Literature DB >> 11457994

Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism.

Philippe Thullier1,2, Caroline Demangel2, Hugues Bedouelle2, Françoise Mégret2, Alain Jouan1, Vincent Deubel2, Jean-Claude Mazié2, Pierre Lafaye2.   

Abstract

Dengue virus infections are a growing public health concern and strategies to control the spread of the virus are urgently needed. The murine monoclonal antibody 4E11 might be of interest, since it neutralizes dengue viruses of all serotypes by binding to the 296-400 segment of the major dengue virus envelope glycoprotein (DE). When phage-displayed peptide libraries were screened by affinity for 4E11, phage clone C1 was selected with a 50% frequency. C1 shared three of nine residues with DE(306-314) and showed significant reactivity to 4E11 in ELISA. C1-induced antibodies cross-reacted with DE(296-400) in mice, suggesting that it was a structural equivalent of the native epitope of 4E11 on DE. Accordingly, 4E11 bound to the DE(306-314) synthetic peptide and this reaction was inhibited by DE(296-400). Moreover, DE(306-314) could block dengue virus infection of target cells in an in vitro assay. A three-dimensional model of DE revealed that the three amino acids shared by DE(296-400) and C1 were exposed to the solvent and suggested that most of the amino acids comprising the 4E11 epitope were located in the DE(306-314) region. Since 4E11 blocked the binding of DE(296-400) to heparin, which is a highly sulfated heparan sulfate (HSHS) molecule, 4E11 may act by neutralizing the interaction of DE(306-314) with target cell-displayed HSHS. Our data suggest that the DE(306-314) segment is critical for the infectivity of all dengue virus serotypes and that molecules that block the binding of DE(306-314) to HSHS may be antiviral reagents of therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457994     DOI: 10.1099/0022-1317-82-8-1885

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  45 in total

1.  Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.

Authors:  David W C Beasley; Alan D T Barrett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses.

Authors:  Michael R Holbrook; Robert E Shope; Alan D T Barrett
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

3.  Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

5.  Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.

Authors:  James D Brien; Soila Sukupolvi-Petty; Katherine L Williams; Chia-Ying Kao Lam; Michael A Schmid; Syd Johnson; Eva Harris; Michael S Diamond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

6.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

7.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

9.  Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins.

Authors:  Pei-Gang Wang; Mateusz Kudelko; Joanne Lo; Lewis Yu Lam Siu; Kevin Tsz Hin Kwok; Martin Sachse; John M Nicholls; Roberto Bruzzone; Ralf M Altmeyer; Béatrice Nal
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

10.  Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).

Authors:  Andréa N M Rangel da Silva; Eduardo J M Nascimento; Marli Tenório Cordeiro; Laura H V G Gil; Frederico G C Abath; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.